This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Kent W. Small, MD
Charleston, SC

Arch Ophthalmol. 1992;110(1):13.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—I read with great interest the article in the March 1991 issue of the ARCHIVES by Sakamoto et al.¹ However, the enzyme deficiency quoted by Sakamoto et al for type 1 primary hyperoxaluria was incorrect. Danpure et al,² in 1986, established that the primary enzymatic deficiency is hepatic peroxisomal alanine:glyoxylate aminotransferase (AGT; EC 2.6.1.44). The decreased -ketoglutarate glyoxylate carboligase quoted by Sakamoto et al is caused by secondary mitochondrial damage.³ More recently, Purdue et al^4,5 and Nishiyama et al⁶ have precisely defined the molecular defect in this disease, further confirming that the primary abnormality is in AGT. In about 30% of patients with type 1 primary hyperoxaluria, a mutation exists which causes AGT, once synthesized, to be rerouted from its normal location in the peroxisome to the mitochondria (so-called targeting defect). These researchers have also mapped the genomic clone encoding AGT to . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?